Jonathan E. Brammer

Associate Professor, T-Cell Lymphomas

Ohio State University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A) Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.

Year:

2025

Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) has been associated with serious cardiotoxicity, including atrial fibrillation (AF) and other cardiac events. In preclinical models, posttransplant clonal hematopoiesis (CH) frequently parallels or precedes clinical AF, yet whether this is seen in patients or has implications for cardiotoxic risk in long‐term follow‐up is unknown. Methods Leveraging consecutive patients treated with alloHSCT, genotyped using deep‐amplicon sequencing to detect the presence of CH, we assessed the development of new (incident) AF, by CH status. Secondary outcomes were the occurrence of major adverse cardiac events, defined as heart failure, myocardial infarction, AF, symptomatic ventricular arrhythmias, and cardiovascular death after alloHSCT. We also assessed the relation between CH and post‐alloHSCT cancer survival outcomes. Observed incident AF rates were compared with Framingham heart predicted rates. Multivariable regression and survival analyses were used to define the relation between CH and incident AF, major adverse cardiac events, progression‐free survival, and overall survival. We also explored these relationship by specific mutation and by varying variant allele frequency. Results Overall, 201 patients with deep sequencing after alloHSCT were identified (median age, 59 years; 46.3% with hypertension; and 42.3% with CH, including 29.5% with ≥2 mutations). Over a median follow‐up of 35 months, 11.5% of patients developed incident AF, and 29.9% experienced major adverse cardiac events. In those without prior AF, the weighted‐average incidence was 407 per 10 000 person‐years compared with the Framingham‐predicted 63 per 10 000 person‐years (risk ratio, 6.4; P <0.001; absolute excess risk, 344). In follow‐up, increased CH burden was associated with higher risk of incident AF (hazard ratio [HR], 4.0 [95% CI, 1.2–14.1]; P =0.03), cancer‐progression (HR, 2.6 [95% CI, 1.3–5.2]; P =0.006), and death (HR, 2.1 [95% CI, 1.0–4.3]; P =0.047). There was no difference in non‐AF major adverse cardiac events. Conclusions Collectively, these data suggest among patients treated with alloHSCT, the presence of CH appears to portend increased AF risk, though validation in larger prospective studies is needed.

Year:

2025

Purpose: Proliferation of T-follicular helper (T FH ) CD4 + T cells is a postulated pathogenic mechanism for T-cell non-Hodgkin lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by T FH , representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS + cells in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of MEDI-570 in T-NHL. NCI-9930 is a phase I, first-in-human study of MEDI-570 in relapsed/refractory malignant T-NHL known to express ICOS. MEDI-570 was administered intravenously every 3 weeks for up to 12 cycles. Primary endpoints were safety, dose-limiting toxicities (DLT), and recommended phase II dose (RP2D). Secondary and exploratory endpoints included efficacy parameters and various correlative studies. This study is supported by the National Cancer Institute (NCT02520791). Results: Twenty-three patients were enrolled and received MEDI-570 at five dose levels (0.01–3 mg/kg). Sixteen (70%) had angioimmunoblastic T-cell lymphoma (AITL); median age was 67 years (29–86) and the median prior lines of therapies was 3 (1–16). Most common grade 3 or 4 adverse events were decreased CD4 + T cells (57%), lymphopenia (22%), anemia (13%), and infusion-related reactions (9%). No DLTs were observed. The RP2D was determined at 3 mg/kg. Analysis of T-cell subsets showed reductions in CD4 + ICOS + T cells reflecting its effects on T FH cells. The response rate in AITL was 44%. Conclusions: MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS + T lymphocytes.

Year:

2025

Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A)Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.

Year:

2024

Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated. A)Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.

Year:

2024

Purpose: Proliferation of T-follicular helper (T FH ) CD4+ T-cells is a postulated pathogenic mechanism for T-cell non-Hodgkin’s lymphomas (T-NHL). The inducible T-cell costimulator (ICOS) is highly expressed by T FH , representing a potential target. MEDI-570 is a monoclonal antibody against ICOS, which eliminates ICOS+ cells in preclinical models. Patients and Methods: We report the safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of MEDI-570 in T-NHL. NCI-9930 is a phase I, first-in-human study of MEDI-570 in relapsed/refractory malignant T-NHL known to express ICOS. MEDI-570 was administered intravenously every 3 weeks for up to 12 cycles. Primary endpoints were safety, dose-limiting toxicities (DLT) and recommended phase 2 dose (RP2D). Secondary and exploratory endpoints included efficacy parameters and various correlative studies. This study is supported by the National Cancer Institute (NCT02520791). Results: Twenty-three patients were enrolled and received MEDI-570 at five dose levels (0.01 mg/kg to 3 mg/kg). Sixteen (70%) had angioimmunoblastic T-cell lymphoma (AITL); median age was 67 years (29 - 86) and the median prior lines of therapies was 3 (1 - 16). Most common grade 3 or 4 adverse events were decreased CD4+ T-cells (57%), lymphopenia (22%), anemia (13%), and infusion related reactions (9%). No DLTs were observed. The RP2D was determined at 3 mg/kg. Analysis of T-cell subsets showed reductions in CD4+ICOS+ T cells reflecting its effects on T FH cells. The response rate in AITL was 44%. Conclusions: MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.

Year:

2024

Year:

2022

Collaborators (12)

Daniel Addison

-

UNITED STATES
View details

Joseph Tuscano

Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Marcos de Lima

Ohio State University

UNITED STATES
View details

John C. Byrd

UPMC Hillman Cancer Center

UNITED STATES
View details

Julio Chavez

Associate Professor

Moffitt Cancer Center

UNITED STATES
View details

Lillian L. Siu

University Health Network

CANADA
View details

Sonali M. Smith

University of Chicago

UNITED STATES
View details

Harsh Shah

Clinical Assistant Professor

Huntsman Cancer Institute

UNITED STATES
View details

Francine Foss

Yale University

UNITED STATES
View details

Anca Prica

-

CANADA
View details

Jasmine Zain

Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Neha Mehta-Shah

Washington University School of Medicine

UNITED STATES
View details